KALV — Kalvista Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $621.80m
- $411.40m
- 25
- 17
- 80
- 35
Annual income statement for Kalvista Pharmaceuticals, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | 2024 April 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.7 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 53.2 | 57.9 | 96.6 | 111 | 140 |
| Operating Profit | -40.5 | -57.9 | -96.6 | -111 | -140 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -29.2 | -46.2 | -82.3 | -92.9 | -127 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -29.1 | -46.2 | -82.3 | -92.9 | -127 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -29.1 | -46.2 | -82.3 | -92.9 | -127 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -29.1 | -46.2 | -82.3 | -92.9 | -127 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.64 | -2.42 | -3.36 | -3.33 | -3.44 |